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AbstrACt
Introduction Up to 30% of hearing aids fitted to new 
adult clients are reported to be of low benefit and 
used intermittently or not at all. Evidence suggests 
that additional interventions paired with service-
delivery redesign may help improve hearing aid use 
and benefit. The range of interventions available is 
limited. In particular, the efficacy of interventions like 
the Active Communication Education (ACE) programme 
that focus on improving communication success with 
hearing-impaired people and significant others, has not 
previously been assessed. We propose that improved 
communication outcomes associated with the ACE 
intervention, lead to an increased perception of hearing 
aid value and more realistic expectations associated 
with hearing aid use and ownership, which are reported 
to be key barriers and facilitators for successful 
hearing aid use. This study will assess the feasibility of 
delivering ACE and undertaking a definitive randomised 
controlled trial to evaluate whether ACE would be a cost-
effective and acceptable way of increasing quality of life 
through improving communication and hearing aid use 
in a public health service such as the National Health 
Service.
Methods and analysis This will be a randomised 
controlled, open feasibility trial with embedded 
economic and process evaluations delivered in audiology 
departments in two UK cities. We aim to recruit 84 
patients (and up to 84 significant others) aged 18 years 
and over, who report moderate or less than moderate 
benefit from their new hearing aid. The feasibility of 
a large-scale study and the acceptability of the ACE 
intervention will be measured by recruitment rates, 
treatment retention, follow-up rates and qualitative 
interviews.
Ethics and dissemination Ethical approval granted 
by South East Coast-Surrey Research Ethics Committee 
(16/LO/2012). Dissemination of results will be via peer-
reviewed research publications both online and in print, 
conference presentations, posters, patient forums and 
Trust bulletins.
trial registration number ISRCTN28090877.
IntroduCtIon 
Age-related hearing impairment is a major 
worldwide public health issue for ageing 
populations.1 It is reported as the third 
most common chronic condition affecting 
approximately 328 million (91%) middle-
aged and older adults,2 over 10 million adults 
in the UK alone.3 4 By the age of 70, 70% will 
have a mild or worse hearing impairment, 
progressively worsening with age.5 Hearing 
impairment is commonly associated with 
reduced quality of life and well-being6–8 
including depression9 and anxiety,10 social 
isolation,8 poor social interactions,11–13 
cognitive dysfunction,14 increased risk 
of developing dementia and reduced 
emotional, behavioural and general social 
strengths and limitations of this study
 ► This will be the first study to evaluate the process-
es involved in delivering the Active Communication 
Education (ACE) intervention in a general  practi-
tioner referral pathway for new National Health 
Service hearing aid users.
 ► If the randomised controlled trial (RCT) is shown to 
be feasible then the data from this study will provide 
critical information that will inform the design of a 
larger RCT to determine the social, clinical and eco-
nomic outcomes of the ACE in this important clinical 
pathway.
 ► The study is powered to allow the SD of the proposed 
outcome measures to be estimated with reasonable 
certainty to inform future sample size calculations.
 ► This study is limited to assessing the feasibility of 
RCT and ACE delivery processes. Ultimately, the test 
of whether the ACE intervention leads to long-term 
communication success, better hearing aid use, 
hearing aid benefit, quality-of-life and economic 
gains, will be tested in a future full-scale RCT.
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well-being.15 In addition, disability in these domains 
is often experienced by normally hearing significant 
others (SOs) living with hearing-impaired people.16–18 
Hearing impairment therefore represents an enormous 
burden on society and the economy.
In high-income countries, the most common treat-
ment is to fit a hearing aid.6 Despite strong evidence that 
hearing aid use is associated with reductions in hearing 
disability noted above,6 19–21 hearing aid use is remark-
ably low.22 23 It is estimated that up to 30% of UK adult 
hearing aid owners do not use them regularly or at 
all.4 24–26 International studies support these data.8 27–29 
Cost implications for the National Health Service (NHS) 
are significant as they provide 80% of UK hearing aids,25 
fitting >300 000 new devices each year of which an esti-
mated 20 000–120 000 are unused. Even with global 
advances in technology, fitting protocols and outcome 
measurements,30 there is little evidence that NHS hearing 
aid use and the expected gains in benefit and quality of 
life have improved over the last decade19 25 and treatment 
continues to focus primarily on technology.
A recent systematic review of additional treatment 
found very low quality evidence that self-management 
and service delivery interventions may be of benefit in 
auditory rehabilitation.31 However, the authors found no 
studies that examined the effect of these sorts of interven-
tions on hearing aid use.
Reasons for hearing aid non-use are complex.32 
Research has identified psychosocial factors important 
for successful aural rehabilitation including personal and 
societal attitudes to hearing-impairment33 patient involve-
ment in decision making34–37 and expectations of benefit 
and communication success in a range of communication 
situations.38 39 Key barriers and facilitators to successful 
hearing aid use have been identified as being related to 
expectations of benefit and meaningful participation in 
everyday life.40 41 The WHO’s International Classification 
of Functioning, Disability and Health42 provides a func-
tional description of difficulties (related to these expecta-
tions) experienced by hearing-impaired people and their 
hearing communication partners, for example, avoid-
ance of difficult listening situations that lead to ‘activity 
limitations’ and ‘participation restrictions’.
One intervention that is designed to reduce these limita-
tions and restrictions is the Active Communication Educa-
tion (ACE) programme (the focus of this paper). The 
ACE trains participants to develop solutions to specific 
difficult communication scenarios that commonly lead to 
their avoidance of or reduced participation in important 
activities. The effectiveness of ACE as an alternative inter-
vention to a hearing aid has been evaluated and two small 
studies demonstrate ACE benefits in improving commu-
nication function and hearing-related quality of life.43 44 
ACE effectiveness as an adjunct to hearing aid fitting has 
not been evaluated, although there is some weak evidence 
that supports its use in this context,43 that is, long-term 
improvements in using communication strategies being 
associated with hearing aid users.
A systematic review of group communication 
programme effectiveness conducted in 2005,44 revealed 
just nine small and methodologically poor studies. The 
review reported weak evidence for short-term benefits 
related to reduced hearing disability; improvements in 
quality of life; hearing aid use and communication func-
tion45 when interventions were delivered in concert with 
a hearing aid. The authors concluded that there was a 
clear need for large sufficiently powered randomised 
controlled studies to determine short-term and long-
term benefits of adult communication rehabilitation 
group interventions as an adjunct to hearing aid fitting. 
Such a study has yet to be completed. Evidence that post-
dates this 2005 review does little to change the situation 
providing only weak additional evidence for moderate 
gains in hearing loss-related quality of life for communi-
cation-based group interventions.46 There are indications 
that group rehabilitation programmes like ACE have the 
potential to realise economic gains for service providers. 
For example, Abrams47 estimated that a hearing aid 
plus a 4-week group rehabilitation programme reduced 
the treatment cost per quality-adjusted life-year (QALY) 
gained by more than half; the cost of implementing the 
rehabilitation programme was <6% of the total rehabili-
tation cost per patient. Even so, with no strong evidence 
that such interventions delivered as an adjunct to hearing 
aid fitting are clinically worthwhile, they are not routinely 
offered in public or private hearing healthcare sectors in 
the UK.
In summary, there is some low-quality evidence that 
ACE and similar programmes improve communication 
function and quality of life and these outcomes may be 
enhanced when delivered in conjunction with a hearing 
aid. Communication programmes involve a substan-
tial commitment on the part of participants and those 
who run and pay for them. Recent evidence shows that 
it is effective and feasible to deliver ACE as an alterna-
tive intervention in Australia and Sweden.43 48–50 There 
is now a need to establish whether reported clinical 
and economic benefits of ACE and communication 
programmes like ACE can be achieved in the context of 
NHS hearing aid provision. This protocol for The ACE 
to HEAR study (ACEto improve HEARing) is intended 
to deliver ACE to unsuccessful or struggling new NHS 
hearing aid users, 3 months postfitting, in order to assess 
whether a large RCT designed to evaluate the effective-
ness of ACE in improving hearing aid benefit within the 
UK NHS is feasible.
MEthods And AnAlysIs
This protocol was developed and is reported according 
to the Standard Protocol Items for Randomised Trials 
statement.51
study aim
The aim of this study is to determine the feasibility of 
delivering a future, full-scale randomised controlled trial 
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(RCT) to evaluate ACE plus treatment-as-usual versus 
treatment-as-usual alone, within the UK NHS in two UK 
cities. Treatment-as-usual is defined as a referral from 
a patient’s GP to audiology services to treat permanent 
hearing loss. It comprises up to two appointments for 
hearing aid fitting and a third face-to-face or telephone 
follow-up appointment.
study objectives
Objectives will evaluate ACE delivery and trial delivery 
processes.
ACE delivery objectives
1. To assess ACE uptake rates, eligibility and acceptability 
of clinic location (between and within the two study 
sites) for participants and SOs.
2. To evaluate the level of ACE attendance and retention 
among participants randomised to the ACE arm of the 
study.
3. To assess acceptability of ACE with participants, SOs 
and audiologists.
4. To assess capability, capacity and willingness of audi-
ology departments to support delivery of ACE within 
existing services.
5. To assess intervention fidelity of delivering ACE.
Trial delivery objectives
1. To assess RCT recruitment rates, evaluate the randomi-
sation process and time to accrue ACE groups.
2. To assess the acceptability of study processes to partic-
ipants, SOs and audiologists (ie, those related to re-
cruitment, the feasibility of identifying struggling hear-
ing aid users, randomisation process, data collection, 
measurement of ACE fidelity and acceptability).
3. To explore patient-reported outcome measures 
(PROMs) and estimate likely SD, including quali-
ty-of-life tools (EQ-5D-5L; Short-Form 36 (SF-36)) and 
a bespoke healthcare resource use/acceptability/utili-
ty questionnaire for use in an intended full-scale RCT.
study design
This study commenced on 1 February 2017 and is of 
24 months duration. The study design is a randomised 
controlled, open feasibility trial with embedded economic 
and process evaluations delivered in one audiology 
department in each of two UK cities. The design of the 
trial is shown in figure 1.
study setting
Study sites for this feasibility study are the Audiology 
Departments at York Hospital (YH), York Teaching 
Hospitals NHS foundation Trust and the Bradford Royal 
Infirmary (BRI), Bradford Teaching Hospitals NHS Foun-
dation Trust.
study population
The study population will consist of adult patients aged 
18 years or over, receiving treatment-as-usual delivered 
in one of the two participating centres. They will be 
considered potentially eligible if all of the following eligi-
bility criteria apply at their 3-month postfitting follow-up 
appointment.
Inclusion criteria
a. Moderate or less than moderate benefit, defined by 
International Outcomes Inventory for Hearing Aids 
(IOI-HA) question 2.52 53
b. Hearing impairment: pure-tone average better ear 
thresholds at 500, 1000, 2000 and 4000 Hz of >25 dB 
HTL.
c. No significant self-reported history of neurological 
impairment.
d. Willing to provide written informed consent.
e. Able to provide written informed consent.
f. Able to take part in the intervention by understanding 
and using spoken English.
g. Able to self-complete the English language outcome 
measure tools.
h. The following inclusion criteria for SOs will be assessed:
a. A spouse or other family member who lives with or 
is a carer for a patient recruited to the study.
Exclusion criteria
a. Severe or profound bilateral hearing impairment. 
Pure-tone better ear average thresholds measured 
at 500, 1000, 2000, and 4000 Hz of >85 dB Hearing 
Threshold Level (HTL), since experience48 suggests 
this group of patients may struggle to effectively partic-
ipate in the intervention setting.
b. Significant ongoing ear-related health or mental 
health issues that, in the audiologist’s or associate audi-
ologist’s professional opinion, would preclude hearing 
aid fitting or attendance at ACE sessions.
c. Unable or unwilling to give written informed consent.
In addition, SOs will be excluded if they are unable or 
unwilling to give written informed consent.
Patients who do not have a SO or family member able 
to attend the ACE sessions are still eligible to participate 
in the study.
sample size calculation and recruitment
As this is a feasibility study, the main purpose is to assess the 
acceptability and feasibility of conducting this study, with a 
view to designing and conducting a future full-scale trial.54 
Six ACE groups are planned with up to seven patients in each 
(five minimum). This leads to a maximum sample size of 44 
patients and up to 44 SOs for the ACE intervention arm, and 
44 in the control arm (n=88). This sample size will allow the 
SD of the proposed outcome measures to be estimated with 
reasonable certainty to inform future sample size calcula-
tions.54 Collectively, the two study sites fit approximately 4300 
hearing aids a year and based on their experience we esti-
mate 10% will require extra help at follow-up and be eligible 
for inclusion. Recruitment of patients commenced on 1 
April 2017 and is now underway. The recruitment window is 
currently planned to end on 28 February 2018 and there is 
potential to extend this phase until 30 April 2018 if necessary.
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randomisation
Eligible, consenting patients from the same study site who 
have completed baseline assessments will be randomised 
by a remote, centralised randomisation service (provided 
by York Trials Unit) in batches of 10–14 (intervention:con-
trol ratio of 1:1) using block randomisation in a single large 
block per batch. Following randomisation, a letter outlining 
the next steps will be sent to participants. For those allocated 
to the ACE arm, this will contain an invitation for them and 
their SO to attend five ACE sessions, including details of the 
venue, times and information.
blinding
By the nature of the interventions used within this study, 
blinding of the participants and facilitator is not possible. 
The research team responsible for data analysis and 
reporting will be blinded where possible.
Intervention allocation
Consenting participants will be randomly allocated to 
either:
 ► treatment-as-usual: participants randomised to receive 
treatment-as-usual will continue to receive usual care 
delivered by their service.
 ► ACE plus treatment-as-usual: participants randomised 
to receive the ACE plus treatment-as-usual, will attend 
five 2 hours weekly sessions of the ACE programme, 
developed in Australia48 and will continue to receive 
usual care delivered by their service.
Figure 1 ACE to HEAR study flow diagram. The diagram was developed using Consolidated Standards of Reporting Trials 
guidelines (http://www.consort-statement.org/) and indicates the main processes of the trial, their relationship with the outcome 
measures and their timing. ACE, Active Communication Education; IOI-HA, International Outcomes Inventory for Hearing Aids; 
IOI-HA-SO, IOI for hearing aids: version for SO; IOI-AI, International Outcomes Inventory for Alternative Interventions; IOI-AI-
SO, IOI for Alternative Interventions: vwesion for SO; SAC, Self-Assessment of Communication; SF-36, Short-Form 36; SO, 
significant other; SOS-HEAR, Significant Other Scale for Hearing Disability.  on
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The ACE programme will be delivered as described 
in the published ACE manual55 by a trained facilitator 
to groups of hard of hearing people and SOs where 
possible. The same audiologist facilitator will deliver ACE 
to all groups.
ACE consists of six modules based on everyday commu-
nication activities known to be problematic for hard of 
hearing adults: module 1: communication needs analysis; 
module 2: conversation in background noise; module 3: 
conversation around the house; module 4: communica-
tion with difficult speakers; module 5: listening to other 
signals and module 6: listening to public-address systems.
Through the use of demonstrations, practical exercises, 
discussion and problem solving, participants and SOs 
will learn individual problem-solving skills which can be 
applied in a range of novel situations and discuss the use 
of communication strategies, lip reading skills, clarifica-
tion skills and assistive technology.
Intervention fidelity
Assessment of the fidelity to the ACE training of the audi-
ologist facilitator and the delivery of the ACE programme 
will follow guidance from the NIH Behaviour Change 
Consortium,56 and conducted in a pragmatic approach 
mirroring the way fidelity of an educational programme, 
such as ACE, would be realistically assured in an NHS 
context. The trainers will reflect on the training sessions; 
fidelity of ACE delivery will be facilitated by supervision 
of the audiologist for the first session, with feedback and 
self-reflection used to address any issues; fidelity of ACE 
delivery will then be assessed via a self-monitoring form 
recording on a 1–4 scale (poor–good) of their adher-
ence to the ACE manual for each module across all 
sessions.
Intervention compliance
Measuring compliance is challenging in complex inter-
ventions such as this, where there are a number of 
interacting elements (such as the influences of the ACE 
facilitator, participants’ significant other, a varied selec-
tion of ACE module topics worked on and each individ-
uals’ perceptions of their (or their SO's) disability and 
treatment benefit). The intervention to be delivered is 
defined in the ACE manual55 and our understanding 
(measurement) of what is actually delivered will be 
informed by the fidelity measures above, weekly atten-
dance logs and weekly session records. ACE participants 
and SOs will self-report goal setting for each module and 
the number of goals achieved during the programme, 
the number of completed exercises (homework) will be 
reported providing an additional measure of the level of 
engagement or compliance with the programme that is 
focused on the participant and their SOs.
Concurrent treatments
Any additional treatments identified will be available 
to both arms when necessary (eg, hearing aid repairs, 
replacement batteries, etc). The bespoke resource use 
questionnaire (see below) will allow us to monitor addi-
tional treatment accessed during the study.
outcome measures
Figure 1 shows the main processes of the trial, their rela-
tionship with the outcome measures and their timing. 
Data will be collected at baseline (prior to randomisa-
tion); during all ACE sessions and after ACE session 5 for 
ACE participants and at an equivalent time for treat-
ment-as-usual participants; and approximately 3 months 
post randomisation (6 months post hearing aid fitting).
The feasibility and the potential for a future large-
scale study design (the study’s aim) will be measured by 
recording and evaluating:
ACE delivery outcomes
1. Attendance: Attendance rates of participants and SOs at 
ACE sessions will be measured and who attends ACE 
session with the participant will be recorded (objective 
2).
2. Fit of ACE with existing variations in service delivery 
models: comparison of attendance at ACE delivered at 
different study sites and their satellite clinics and the 
effect of using telephone or face-to-face follow-up ap-
pointments will be recorded (objectives 1 and 4).
3. Can ACE be delivered as intended in the ACE proto-
col? This will be assessed through: (i) time taken to 
train the ACE facilitator successfully; (ii) number of 
ACE goals achieved by participants and (iii) facilita-
tor’s adherence to the ACE protocol (fidelity) (objec-
tive 5).
4. Acceptability: bespoke acceptability questionnaire re-
garding study processes, designed to explore partici-
pant and SO thoughts regarding the study including; 
ACE session organisation, session content, being 
approached and informed about the study and com-
pleting the questionnaires. The questionnaire is ad-
ministered to participants and SOs at the final ACE 
session and at a comparable time for the questions for 
treatment-as-usual arm (objectives 3 and 4).
RCT delivery outcomes
1. Recruitment: number of follow-up cases in GP referred 
pathway; number of follow-up cases in GP referred 
pathway struggling with their hearing aid; number of 
and reasons for exclusions; number of patients who 
decline to participate and reason for declining; num-
ber who miss ACE intervention window (ie, unable to 
attend an ACE group within 1–3 weeks after rando-
misation); number given an appointment for an ACE 
group session and number of consented participants 
who fail to attend ACE sessions (objectives 6 and 7).
2. Allocation: time taken to recruit and logistics of recruit-
ing an optimally sized and located ACE group; time 
ACE started after randomisation (ACE intervention 
window); (objective 6).
3. PROM data: completion of the outcome measures 
below at each time-point will be recorded as well 
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International Outcomes Inventory fo Hearing Aids as 
extent of missing data within each outcome measure 
(objective 8).
Patient-reported outcome measures
 ► International Outcomes Inventory fo Hearing Aids (IOI-
HA)52: a seven-item questionnaire designed to eval-
uate the effectiveness of hearing aid treatments. The 
domains covered are: daily use; benefit; residual 
activity limitations; satisfaction; residual participa-
tion restrictions; impact on others and quality of life. 
Responses are assigned a value from 1 to 5 and values 
summed. Higher scores indicate a more favourable 
outcome.
 ► International Outcomes Inventory for Alternative Interven-
tions (IOI-AI)57: a version of the IOI designed for use 
for non-hearing aid-based interventions such as ACE, 
covering the same domains as the IOI-HA.
 ► Self-Assessment of Communication58: designed to 
measure the effect of hearing loss and hearing aid 
outcomes. This 10-item instrument covers questions 
about communication problems using a Likert scale 
ranging from 1 (‘almost never’) to 5 (‘practically 
always’). A percentage score is calculated by multi-
plying the raw score by 2, subtracting 20 and multi-
plying by 1.25.
 ► EQ-5D-5L59 60: a standardised generic instrument 
for describing and valuing health in terms of five 
dimensions (mobility, self-care, usual activities, pain/
discomfort and anxiety/depression) using five levels 
of severity. Overall health on the day is also rated by 
the respondent on a 0–100 vertical visual analogue 
scale.
 ► SF-3661: a generic health measure with 36 items 
assessing eight health concepts: physical functioning; 
role limitations due to physical problems; general 
health perceptions; vitality; social functioning; role 
limitations due to emotional problems; general 
mental health and health transition.
The following will be completed by participants’ SOs 
only:
 ► IOI-AI: version for significant others56: a version of the IOI 
designed for use with SOs and non-hearing aid-based 
interventions covering the same seven domains as the 
IOI-HA.
 ► IOI for hearing aids: version for SOs56: an extension of 
the IOI-HA for use with the SO covering the same 
seven domains as the IOI-HA.
 ► Significant other scale for hearing disability16: a 27-item 
self-report tool, which assesses third-party disability 
in spouses of older people with hearing impairment. 
It measures the effects of hearing impairment on the 
SO in the following domains: changes to communica-
tion; communication burden; relationship changes; 
going out and socialising; emotional reactions to 
adaptations; concern for partner. It uses a 5-point 
response scale: 0=no problem to 4=a complete 
problem.
The feasibility of collecting postal questionnaire data at 
each time point will be evaluated. Table 1 shows the data 
collection schedule.
screening and enrolment
Patients attending Audiology Clinics at YH and BRI will 
be approached to take part. Treatment-as-usual provided 
at the posthearing aid fitting follow-up will be according 
to site and therefore the recruitment process will vary 
slightly at each site:
 ► York: patients will be followed up via a telephone 
interview. Eligibility will be checked during telephone 
interview and from medical records. Details of eligible 
and interested patients will, with their permission, 
be passed onto a non-ACE researcher who will post 
out a patient information sheet (PIS) and conduct a 
telephone follow-up call a few days later to see if still 
interested. Contact information is provided in the PIS 
so that the patient has opportunity to ask questions 
regarding the study. If willing to participate, informed 
consent and baseline questionnaire will be completed 
by post. SOs of patients who are recruited at York will 
receive a SO-specific PIS, consent form and baseline 
questionnaire by post to be returned in a freepost 
envelope.
 ► Bradford: patients will be offered a face-to-face follow-up 
appointment 3 months post hearing aid fitting. Eligi-
bility will be checked at this appointment and from 
medical records. Details of eligible and interested 
patients will be passed onto a non-ACE researcher 
who will provide a PIS and discuss the study. The 
patient will have the opportunity to ask questions and 
if willing, provide informed consent and complete 
a baseline questionnaire. If further consideration is 
required, the patient will be contacted by telephone 
call a few days later to see if still interested. In addi-
tion, if an SO attends the appointment with a patient, 
they will be provided with a SO-specific PIS, consent 
form and baseline questionnaire. Otherwise the docu-
mentation will be given to the patient to pass on to 
their SO or posted out.
We will monitor the proportion of patients referred to the 
treatment-as-usual pathway during the study recruitment 
who subsequently do not attend or are not contactable by 
telephone for their post-HA fitting follow-up in order to esti-
mate how many referrals may potentially be lost to recruit-
ment. We will liaise with audiologists to identify reasons for 
non-attendance where possible.
data collection and management
All data for the participant outcome measures will be 
collected by self-completed questionnaires returned by 
post or in secure boxes within the audiology clinics. Partic-
ipants and SOs who fail to return their postal question-
naires will receive one reminder letter. Participants may 
also be asked to complete a questionnaire over the tele-
phone, or asked to provide any missing data if required. 
Data from these paper forms will then be entered into a 
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master database for the trial using either optical scanning 
techniques or entered manually.
Participants may withdraw from all or any aspects of the 
study without influencing their future care or treatment. A 
brief update of how the study is progressing will be sent out 
in order to maintain participant engagement with the study.
All information collected during the course of the trial 
will be kept strictly confidential. Information will be held 
securely on paper and electronically at York Trials Unit. 
All trial data will be identified using a unique trial iden-
tification number. Analytical datasets will not contain 
any identifiable information. Data will be archived for a 
period of at least 10 years following the end of the study.
statistical analysis
A single analysis will be conducted at the end of the trial 
using Stata V.13 or later. Data summaries and analyses 
will inform the design of a full-scale RCT of the inter-
vention. Baseline data will be summarised by trial arm, 
using descriptive statistics for continuous data (mean, 
SD, median, minimum, maximum, number missing) and 
counts and percentages for categorical data. Recruitment 
rates will be reported monthly and overall, and by site. 
The flow of participants through the trial will be detailed 
in a Consolidated Standards of Reporting Trials flow 
diagram and referral, consent and attendance rates will 
be summarised overall and by site using counts, percent-
ages and 95% CIs.
The number of ACE sessions attended will be 
summarised alongside any SOs who attended the sessions. 
Summaries will be provided overall, by site/clinic and by 
whether follow-up appointments were made as single 
or block booking. Acceptability data using Likert scales 
Table 1 Data collection schedule Data are collected approximately 3 months posthearing aid fitting (baseline); at each ACE 
session 1–5 for the intervention arm and at a time equivalent to ACE week 5 for the treatment-as-usual arm; and approximately 
6 months posthearing aid fitting
Study period Recruitment Allocation Postallocation
Time point Baseline 0
ACE 
week 1
ACE 
week 2
ACE 
week 3
ACE 
week 4
ACE 
week 5 6 months
Recruitment 
  Eligibility •
  Informed consent • 
  Optional qualitative 
study consent
• 
  Allocation • 
Assessments
  Demographics • 
  IOI-HA • • • 
  SAC • • 
  EQ-5D-5L • • 
  SF-36 • • 
  Resource use • • 
  IOI-AI* • • 
  ACE participant 
attendance*
• • • • • 
  ACE SO attendance~ • • • • • 
  IOI-AI-SO*† • • 
  IOI-HA-SO† • • • 
  SOS-HEAR† • • • 
  Acceptability 
questionnaire
• 
  Qualitative interviews 
(participant and SO)
• 
  Qualitative interviews 
(audiologists)
• 
*ACE arm only. 
† Significant others only.
ACE, Active Communication Education; IOI-AI, International Outcomes Inventory for Alternative Interventions; IOI-HA, International Outcomes 
Inventory for Hearing Aids; IOI-HA-SO, IOI for hearing aids: version for SO; SAC, Self-Assessment of Communication; SF-36, Short-Form 36; 
SO, significant others; SOS-HEAR, Significant Other Scale for Hearing Disability.
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at 6 months, for participants, SOs and audiologists will 
be summarised separately using summary statistics and 
presented graphically using bar charts, by trial arm.
The number of participants withdrawing from the ACE 
intervention and/or the trial and any reasons for with-
drawal will be summarised.
The time taken to train audiologists to deliver ACE and 
the number of ACE goals achieved by participants will be 
summarised. Fidelity scores (from self-monitoring forms) 
will be summarised overall and by session. The proportion 
of training and ACE intervention delivered as intended, 
as well as any adaptations to training/intervention will be 
reported. Variations in dose of ACE intervention will be 
measured through ACE attendance and attrition data.
Questionnaire return rates at each time point will be 
presented overall and by trial arm. PROMs at each time 
point will be summarised descriptively overall, by trial arm, 
and by ACE group for participants allocated to receive 
the ACE intervention. SD will be presented with 80% CIs 
to inform future sample size calculations. The proportion 
of participants at the floor and ceiling of each measure, 
at each time point, will be reported along with the stan-
dardised response mean (SRM) to measure the sensitivity 
of each questionnaire to detect change. The SRM will be 
calculated as mean change in scores or values divided 
by the SD in change scores.62 Questionnaire completion 
times (from self-report) will be summarised as a consid-
eration for instruments going into the full-scale evalua-
tion. Missing data will be reported as a proportion of the 
total expected data set for each measure and will inform 
feasibility.
Qualitative data
Following delivery of all the ACE intervention sessions:
 ► The facilitator will be interviewed to explore the 
training and implementation process and their expe-
riences of delivering ACE including barriers/facilita-
tors to adhering to the ACE protocol.
 ► Up to three audiologists from both study sites (up to 
six in total) will also be interviewed, exploring the 
capability, capacity and willingness of their audiology 
departments to support the ACE study within their 
existing services. The acceptability of study processes 
will also be explored.
 ► A sample of 10–12 participants in the ACE interven-
tion arm and four participants in the control arm 
(with their SOs if willing) will also be interviewed 
as soon as possible after the completion of the ACE 
sessions. We will purposively select participants to 
ensure a mix of those with good/poor hearing aid 
outcomes (measured at the fifth and final ACE session 
and equivalent control arm time point, see figure 1 
for outcome measures) as well as ensuring we include 
some participants who dropped out of the sessions/
study, ensuring a wide range of views are collected. 
Control arm participants will include those who have 
dropped out from the study where possible, allowing 
us to explore reasons for this. SOs will be interviewed 
as part of a dyad with the participant. Semi-structured 
interviews will explore the acceptability of the ACE 
(eg, venue, timing, content), its perceived impact 
(reflecting on hearing aid outcomes) with ACE inter-
vention arm participants; and views on study processes 
(eg, recruitment, outcome measures and timing) with 
ACE intervention and control arm participants.
Interviews will be audio-recorded, transcribed verbatim 
and analysed (with NVivo-11) by the research team led 
by CJ, using the Framework approach,63 which is particu-
larly useful for analysing qualitative data in a pragmatic 
yet systematic way, where theoretical development is not 
needed. The steps are familiarisation, construction of 
a thematic framework, indexing and charting the data, 
mapping and interpretation.
Economic analysis and quality of life data
A full cost-effectiveness analysis will not be conducted as 
this is a feasibility trial, thus the study is not powered to 
detect significant differences.
The costs of implementing the ACE intervention will 
be estimated and the potential resource implications 
versus usual care will be explored. Resource use will be 
summarised by resource use type (eg, GP appointments, 
outpatient appointments) and appropriate unit costs to 
be applied to each resource use type will be identified. 
These will be sourced from a combination of local cost-
ings and national databases.64
The costing approach will take a broad analytical perspec-
tive accounting for NHS costs and for those observed by 
patients, although this cost will be presented separately. It 
is anticipated that additional resources used in the ACE 
intervention arm will largely be NHS staff time and travel/
time for patients and SOs, patients and SOs use of primary 
and secondary NHS care, any private treatments attended, 
whether related to their hearing or for any other reason, 
changes to medication and employment or recreational 
activities. A draft resource use questionnaire based on these 
anticipated additional resources was designed for this study. 
The questionnaire will be developed further and tested 
during the feasibility trial to ensure that all relevant and 
necessary data can be collected to establish a reliable and 
valid tool with which to capture resource use for a future 
full economic evaluation.
Methods to estimate an incremental cost-effectiveness 
ratio for the ACE intervention versus treatment-as-usual 
alone in terms of QALYs will be explored. No health-related 
quality of life assessment tool is currently sufficiently sensi-
tive to all populations, and in the field of hearing health, 
there has been limited research to identify the most effective 
tool. In the UK, NICE advocates the used of the EQ-5D for 
generating QALYs, although it is acknowledged that this is 
not always the most sensitive tool for particular populations 
for whom the majority of its dimensions may not apply.65 In 
the US analysis of a 4-week rehabilitation programme noted 
above,47 the SF-36 was used to generate QALYs rather than 
the EQ-5D, with the SF-36 showing a reduction in the cost 
per QALY in favour of the intervention. For the present 
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feasibility trial, both assessments will be used to elicit QALYs 
and a comparison will be made between the outcomes of the 
two measures. This will enable a decision to be made as to 
which tool would be most appropriate in the full-scale trial.
The feasibility work will also be used to help to identify 
any patterns of missing data and any issues relevant for 
sensitivity analysis, which will influence statistical plans 
for dealing with imprecision and other uncertainties in 
the full RCT. For example, data can be bootstrapped to 
account for the expected skewness evident in economic 
cost data. The data collected as part of this feasibility study 
will be used to inform subsequent pretrial modelling.
Adverse events
Risks within this study are considered to be minimal. It is 
considered highly unlikely that the ACE intervention arm 
will suffer any adverse consequences as a result of receiving 
the ACE plus treatment-as-usual. Nevertheless, interviews 
with ACE participants, the ACE facilitator and ACE ques-
tionnaire data will be used to monitor this eventuality.
trial monitoring and oversight
Due to the low risk nature of this trial, approval has been 
obtained to set up one independent steering and moni-
toring committee to undertake the roles traditionally 
undertaken by the Trial Steering Committee and Data 
Monitoring and Ethics Committee. Regular meetings of 
a Study Management Group will take place to oversee 
the progress of the study and review recruitment. We will 
establish a Project Advisory Panel (PAP) with between two 
and four hard of hearing adults or hearing spouses that 
will meet a minimum of five times over the duration of 
the project. The PAP is a group of patients, service users, 
carers and lay members of the public whose role is to 
support and advise the Study Management Group on all 
aspects of the study’s progression and management.
Patient and public involvement
Three patient and public involvement (PPI) activities 
informed the development of this application. First, a 
funded public engagement event about public percep-
tions of hearing impairment was held at the Thackeray 
Medical Museum in Leeds. This event helped to inform 
the research question. Participants identified a need for 
wider availability of treatments additional to hearing aids 
and that non-technological interventions for hear-
ing-impaired people were a priority. Delegates identi-
fied communication education as a useful addition to 
hearing aid use for many hearing-impaired people and 
their family members. This feedback informed the study 
design in the following way: the choice of an interactive 
communication-based intervention rather than an infor-
mational one; the need to ensure that routine practical 
information about hearing aids and hearing impairment 
is delivered consistently and checked after fitting.
Second, a focus group was held to consult with service-
users on the proposed research question, study design 
and intervention delivery. Four participants were asked to 
discuss (a) study information and consent procedures, (b) 
factors that might encourage or discourage their partici-
pation in the proposed study such as the burden of the 
intervention, (c) types of communication scenarios that 
are important to them, (d) factors that might motivate 
them to be more active communicators. The outcomes 
informed our recruitment strategy to maximise interest, 
commitment and recruitment rates. The group’s views 
helped develop study information sheets and operational 
components of delivering ACE.
Third, the charity Hearing Link, who have extensive 
experience of PPI and managing and delivering group 
interventions of this type, were consulted about involving 
public and patients in operationalising and delivering 
ACE. Patients and service users and carers are involved 
in the conduct of this study as active members of the PAP.
We will present the findings of this study in patient 
forums, Trust bulletins and PPI activities including news-
letters and public interest groups who work and support 
older adults with hearing impairment.
data monitoring and management
Information relating to study participants will be kept 
confidential and managed in accordance with the Data 
Protection Act, NHS Caldicott Guardian, Research 
Governance Framework for Health and Social Care and 
the Research Ethics Committee approval.
Participant details will be stored on a secure pass-
word-protected server located at the University of York, 
for the purposes of assisting in follow-ups during the 
study. All paper data collected from participants will 
be maintained in a safe secure environment at York 
Trials Unit. Paper records will be identified using iden-
tifiers rather than personally identifiable information. 
Analytical datasets will not contain any identifiable 
information.
The confidentiality of the participants, SOs and audi-
ologists interviewed during their qualitative interviews 
will be ensured by assigning a unique identification 
code to electronic sound files and transcripts of inter-
views, known only to the qualitative researcher and 
appropriate members of the research team. Any quotes 
published will be anonymous further protecting partici-
pant confidentiality.
EthICs And dIssEMInAtIon
Since the study started in February 2017, three Health 
Research Authority (HRA)-approved amendments were 
added to the protocol and are included in the final 
version reported here:
1. Revised the fidelity check tool. This was considered a 
non-substantial amendment.
2. Remove inclusion criteria of <3 hours hearing aid use 
a day and adjusted inclusion criteria to include moder-
ate benefit. We also gained approval to distribute study 
information flyers to study site staff and patients. These 
were considered substantial amendments.
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3. Developed a study information flyer to be sent to pa-
tients not contactable by telephone for follow-up at the 
York study site. This was considered a non-substantial 
amendment.
The proposed study will be conducted in accordance 
with the MRC Guidelines on Good Clinical Practice in 
Clinical Trials.
The results from this study will be submitted to the 
funders, peer-reviewed journals, presented at relevant 
meetings/conferences and within the participating and 
other audiology departments. We also intend to present 
the findings of this study in patient forums, Trust bulle-
tins and PPI activities including newsletters and public 
interest groups who work and support older adults with 
hearing impairment.
ConClusIon
This will be the first RCT of this type of group commu-
nication programme in the context of a public health 
service and as an adjunct to hearing aid fitting. The 
impact of this study will ultimately be realised by a larger 
fully powered RCT designed to determine the effective-
ness of the ACE intervention in improving hearing aid 
benefit for hearing aid users within the NHS GP referral 
for a hearing aid pathway in the UK. The outcomes of this 
study will inform such a RCT.
The feasibility study will be deemed successful if:
1. Seventy per cent of recruitment targets attained for all 
research components.
2. Study consent/retention rates and proposed sample 
sizes, indicate delivery of the full RCT is plausible with-
in a 5-year study period.
3. Ninety per cent of ACE groups of five to seven consent-
ed participants formed within the intervention window 
with participants attending three of five sessions.
4. Economic, acceptability, outcome measure and fidelity 
evaluation data successfully collecte
5. Participants, SOs and audiologists evaluate acceptabili-
ty of the ACE and RCT positively.
(Measures with over 10% missing data maybe modi-
fied/replaced prior to the main trial).
The criteria for success will result in one of following 
outcomes:
1. stop: full-scale RCT not be feasible in NHS setting;
2. continue: feasible with modifications;
3. continue: feasible with no modifications, close moni-
toring;
4. continue feasible as is.
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